GSK plc (GSK) - Financial and Strategic SWOT Analysis Review

GSK plc (GSK) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

GSK plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GSK plc Key Recent Developments

May 14,2024: Department of Health - Abu Dhabi partners with GSK to Establish Regional Vaccine Distribution Hub
May 08,2024: BioVersys and GSK expand their partnership for TB treatment alpibectir
May 08,2024: GSK plc Announces Board Committee Change
May 01,2024: GSK Makes a Strong Start to 2024 with Improving Outlook for the Year

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
GSK plc - Key Facts
GSK plc - Key Employees
GSK plc - Key Employee Biographies
GSK plc - Major Products and Services
GSK plc - History
GSK plc - Company Statement
GSK plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
GSK plc - Business Description
Business Segment: Commercial operations
Overview
Performance
Business Segment: Total R&D
Overview
Geographical Segment: Rest of World
Performance
Geographical Segment: UK
Performance
Geographical Segment: US
Performance
R&D Overview
GSK plc - Corporate Strategy
GSK plc - SWOT Analysis
SWOT Analysis - Overview
GSK plc - Strengths
GSK plc - Weaknesses
GSK plc - Opportunities
GSK plc - Threats
GSK plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
GSK plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
GSK plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 14, 2024: Department of Health - Abu Dhabi partners with GSK to Establish Regional Vaccine Distribution Hub
May 08, 2024: BioVersys and GSK expand their partnership for TB treatment alpibectir
May 08, 2024: GSK plc Announces Board Committee Change
May 01, 2024: GSK Makes a Strong Start to 2024 with Improving Outlook for the Year
Mar 25, 2024: GSK PLC Notice of AGM
Mar 08, 2024: GSK - Board Committee Change
Mar 07, 2024: GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
Mar 05, 2024: GSK PLC GSK Annual Report 2023 on Form 20-F
Feb 29, 2024: GSK Announces Dr Jeannie Lee to Join the Board as Non-Executive Director
Feb 27, 2024: GSK, In Partnership with Schneider Electric, Agrees Virtual PPA with IGNIS to Power Operations Across Europe with Solar Energy
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
GSK plc, Key Facts
GSK plc, Key Employees
GSK plc, Key Employee Biographies
GSK plc, Major Products and Services
GSK plc, History
GSK plc, Other Locations
GSK plc, Subsidiaries
GSK plc, Joint Venture
GSK plc, Key Competitors
GSK plc, Ratios based on current share price
GSK plc, Annual Ratios
GSK plc, Annual Ratios (Cont...1)
GSK plc, Annual Ratios (Cont...2)
GSK plc, Interim Ratios
GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
GSK plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
GSK plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
GSK plc, Performance Chart (2019 - 2023)
GSK plc, Ratio Charts
GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
GSK plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings